Aller au contenu principal
Accès ouvert déclaré 2021 conference-paper

4CPS-339 Intrathecal administration of baclofen for the reduction of spasticity

0Citations signalées — pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Background and importance Muscle spasticity is a consequence of traumatic brain and spinal cord injuries, stroke, cerebral paralysis and multiple sclerosis. It interferes with mobility and causes pain. There are numerous approaches in the treatment of spasticity. Intrathecal baclofen administration, through the positioning of a programmable pump in the abdomen and a catheter near the spinal column, is an option to reduce spasticity. The pump releases the liquid form of baclofen directly into the intrathecal space of the spinal cord, obtaining higher concentrations than oral therapy. Aim and objectives To evaluate the long term efficacy on the decrease in spasticity and improvement in patients’ quality of life treated by neurosurgery until September 2020. Material and methods An analysis was made of medical records of patients treated until September 2020. Data were collected on: diagnosis, baclofen dosage, complications and/or side effects, degree of spasticity and improvement in quality of life. To evaluate spasticity, the Ashworth scale was used, from grade 0 (no increase of tone) to grade 5 (rigid limb in flexion and extension), by measuring the value obtained before implantation of the pump and at follow-up. The care and comfort caregiver survey was used to measure the patient’s ability to perform personal care activities. Results Neurosurgery treated 91 patients, 39 women and 52 men, with an average age of 42 years. The diagnoses are: 31 perinatal hypoxia, 15 multiple sclerosis, 18 post-trauma, 5 surgical complications, 4 transverse myelitis, 4 haemorrhagic events, 3 ischaemic events, 2 genetic causes, 2 cardiac arrests, 2 complications in childbirth, 1 PKAN syndrome, 1 overdose in a drug addict, 1 poliomyelitis, 1 vertebral collapse and 1 post vaccine. Patients received a daily baclofen dosage of 40–1.350 µg. Side effects such as skin rashes were recorded due to overdose, and the appearance of itching and agitation due to too low a dose. Complications related to the pump were pressure sores, infections and reservoir malfunction. Ashworth’s score at follow-up decreased by an average of 2.5 points with a consequent improvement in quality of life, confirmed by the results of the questionnaire. Conclusion and relevance Intrathecal administration of baclofen was an effective system in the treatment of spasticity and had a positive impact on improving quality of life. References and/or acknowledgements Conflict of interest No conflict of interest

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
4CPS-339 Intrathecal administration of baclofen for the reduction of spasticity
Date Crossref
01/03/2021
Éditeur
British Medical Journal Publishing Group
Type
proceedings-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Botulinum Toxin and Related Neurological DisordersCerebral Palsy and Movement DisordersStroke Rehabilitation and Recovery

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.